--- title: "Eli Lilly increases its supply chain layout in China, the Hong Kong Innovative Drugs ETF (159567) rises nearly 1%, institutions are optimistic about the long-term allocation value of the sector" type: "News" locale: "en" url: "https://longbridge.com/en/news/278805640.md" description: "On March 12th, the Hong Kong stock market saw active trading in the innovative drug sector, with the Hong Kong Innovative Drug ETF (159567) rising by 0.95%, and the trading volume exceeding 166 million yuan. Component stocks such as KEYMED BIO-B and Ascentage Pharma-B also experienced gains. Eli Lilly announced plans to invest $3 billion in China over the next decade to expand supply chain capacity, particularly in the production of oral solid dosage forms. Dongxing Securities is optimistic about the medium to long-term allocation value of the innovative drug sector, believing that short-term stock price fluctuations do not change the long-term growth logic of the industry" datetime: "2026-03-12T02:04:14.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/278805640.md) - [en](https://longbridge.com/en/news/278805640.md) - [zh-HK](https://longbridge.com/zh-HK/news/278805640.md) --- # Eli Lilly increases its supply chain layout in China, the Hong Kong Innovative Drugs ETF (159567) rises nearly 1%, institutions are optimistic about the long-term allocation value of the sector On March 12, the Hong Kong stock market opened lower and then rose, with the innovative drug concept continuing to be active. Among the related ETFs, **the Hong Kong Innovative Drug ETF (159567) rose 0.95% as of the time of publication**, with a trading volume exceeding 166 million yuan and active trading during the session. Among the constituent stocks, KEYMED BIO-B rose nearly 3%, Ascentage Pharma-B rose over 2%, and Innovent Biologics rose nearly 2%, with other stocks like Luye Pharma and Fosun Pharma also following suit. **The Hong Kong Innovative Drug ETF (159567)** closely tracks the China Universal Hong Kong Stock Connect Innovative Drug Index (987018), which aims to reflect the operational characteristics of listed companies in the innovative drug sector within the scope of the Hong Kong Stock Connect. This ETF is equipped with two off-exchange connected funds, namely: Yinhua China Universal Hong Kong Stock Connect Innovative Drug ETF Initiated Link A (023929) and Yinhua China Universal Hong Kong Stock Connect Innovative Drug ETF Initiated Link C (023930). In terms of news, **according to The Paper,** following the announcement of capacity upgrades at its Suzhou factory in 2024, Eli Lilly is also increasing its capacity investment in Beijing. On March 11, Eli Lilly announced plans to invest a total of $3 billion over the next decade to comprehensively expand its supply chain capacity in China, creating a local production and supply system for oral solid formulations, focusing on the production capacity of the next-generation oral small molecule GLP-1 receptor agonist orforglipron. Dongxing Securities also pointed out that the stock prices of most innovative drug companies have significantly retreated from their peaks in 2025, with valuations and sentiment at a phase low. However, from the perspective of continuous business development (BD) realization in the industry and the ongoing advancement of BD pipelines, short-term stock price fluctuations have not changed the long-term growth logic of innovative drugs going overseas, **and we remain strongly optimistic about the medium to long-term allocation value of the innovative drug sector.** **** ### Related Stocks - [159567.CN](https://longbridge.com/en/quote/159567.CN.md) - [159506.CN](https://longbridge.com/en/quote/159506.CN.md) - [159570.CN](https://longbridge.com/en/quote/159570.CN.md) - [159615.CN](https://longbridge.com/en/quote/159615.CN.md) - [02162.HK](https://longbridge.com/en/quote/02162.HK.md) - [LLY.US](https://longbridge.com/en/quote/LLY.US.md) - [588250.CN](https://longbridge.com/en/quote/588250.CN.md) - [520880.CN](https://longbridge.com/en/quote/520880.CN.md) - [159892.CN](https://longbridge.com/en/quote/159892.CN.md) - [513120.CN](https://longbridge.com/en/quote/513120.CN.md) - [159849.CN](https://longbridge.com/en/quote/159849.CN.md) - [159316.CN](https://longbridge.com/en/quote/159316.CN.md) - [512010.CN](https://longbridge.com/en/quote/512010.CN.md) - [520690.CN](https://longbridge.com/en/quote/520690.CN.md) - [516500.CN](https://longbridge.com/en/quote/516500.CN.md) - [159102.CN](https://longbridge.com/en/quote/159102.CN.md) - [159992.CN](https://longbridge.com/en/quote/159992.CN.md) - [159837.CN](https://longbridge.com/en/quote/159837.CN.md) - [562050.CN](https://longbridge.com/en/quote/562050.CN.md) - [520500.CN](https://longbridge.com/en/quote/520500.CN.md) - [588130.CN](https://longbridge.com/en/quote/588130.CN.md) - [512290.CN](https://longbridge.com/en/quote/512290.CN.md) ## Related News & Research - [China to Let Firms Set New Drug Prices Based on Clinical Value, R&D Costs and Risks](https://longbridge.com/en/news/282939130.md) - [Cutia Therapeutics’ Botox Rival Meets Phase III Goals in China](https://longbridge.com/en/news/282464943.md) - [Lilly Moves To Expand Obesity Pill Use](https://longbridge.com/en/news/283037631.md) - [Lilly to acquire CrossBridge Bio for up to $300m](https://longbridge.com/en/news/282813734.md) - [Xuanzhu Biopharm Wins Green Light for Phase III Anaprazole Trial in H. pylori](https://longbridge.com/en/news/282752451.md)